Science

SynDevRx brings new tools and fresh thinking to cancer treatment.

We’re developing novel treatments directed specifically towards cancer patients that also have baseline metabolic complications (overweight/obesity, pre-diabetes, T2D). Research shows that improving cancer patients’ metabolic state improves outcomes, but it’s a challenge!

By offering treating oncologists and physicians a simple once-every-two-week subcutaneous injection to their patients that address a major unmet medical need (baseline metabolic dysfunction) we hypothesize we can potentiate standard-of-care treatments for a wide variety of cancers, including breast, prostate, colorectal, liver among others.

Our drug development strategy has three-parts:
1. start with a validated class of drug that has demonstrated clinical activity in cancer and obesity – but had a toxicity problem;
2. tackle the toxicity issues while maintaining drug activity via polymer-drug conjugation; and
3. improve the doctor and patient experience by delivering this new drug on a simple Q14D basis with relatively low volume of infusion.